BRIEF published on 05/08/2024 at 07:05, 6 months 13 days ago SYNLAB Reports Robust Financial Performance in Q1 2024 Adjusted EBITDA Organic Growth Q1 2024 Earnings SYNLAB Financial Performance Medical Diagnostics Industry
PRESS RELEASE published on 05/08/2024 at 07:00, 6 months 13 days ago SYNLAB delivers strong performance in Q1 2024 SYNLAB AG reports strong Q1 2024 results with revenue of €682 million and Adjusted EBITDA margin reaching 18.0%. Strategic priorities and portfolio management drive performance Adjusted EBITDA Revenue Portfolio Management Q1 2024 Results SYNLAB AG
BRIEF published on 04/30/2024 at 15:01, 6 months 20 days ago SYNLAB Italy Resumes Operations After Cyber-Attack Data Security Cyber-attack SYNLAB Italy Operations Resumed Medical Diagnostic Services
PRESS RELEASE published on 04/30/2024 at 14:56, 6 months 20 days ago SYNLAB Italy has restored operations after cyber-attack SYNLAB Italy resumes operations after cyber-attack, gradually restoring services to patients and customers. No impact on operations in other countries. Task force investigates incident Investigation Task Force Cyber-attack SYNLAB Italy Resumed Operations
BRIEF published on 04/19/2024 at 19:11, 7 months 1 day ago SYNLAB AG Reports Cyber-Attack Impact on Operations in Italy SYNLAB Cyber-attack Italy Operations Suspended IT Security Measures Task Force Established Corporate Crisis Management
PRESS RELEASE published on 04/19/2024 at 19:06, 7 months 1 day ago EQS-Adhoc: SYNLAB AG: SYNLAB affected by cyber-attack in Italy SYNLAB AG announces that SYNLAB Italy is affected by a cyber-attack, causing operations in Italy to be largely suspended. A task force is working to restore IT systems Italy IT Systems Task Force SYNLAB AG Cyber-attack
BRIEF published on 03/25/2024 at 07:05, 7 months 27 days ago SYNLAB Reports Solid Financial Performance for FY 2023 Amidst Challenges Financial Performance M&A Activities Organic Growth Annual Results SYNLAB AG
PRESS RELEASE published on 03/25/2024 at 07:00, 7 months 27 days ago SYNLAB delivers robust performance in FY 2023 SYNLAB AG reports robust financial performance in 2023 with revenue of €2.64 billion, driven by 6.4% organic growth and adjusted EBITDA margin of 16.6%. Read the full press release for details Financial Performance Adjusted EBITDA Margin Organic Growth FY 2023 Results SYNLAB AG
PRESS RELEASE published on 11/08/2023 at 07:30, 1 year ago Continued strong performance in the third quarter of 2023
PRESS RELEASE published on 11/02/2023 at 17:46, 1 year ago SYNLAB AG publishes Joint Reasoned Statement on public acquisition offer by Cinven
Published on 11/21/2024 at 13:30, 22 minutes ago AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 22 minutes ago Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 52 minutes ago Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 52 minutes ago Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 52 minutes ago Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 12:35, 1 hour 17 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 37 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 6 hours 54 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 32 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 7 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 7 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
